Core Insights - The 2025 National Medical Insurance Drug List includes 114 new drugs, with 50 being innovative drugs, achieving an overall success rate of 88%, a significant increase from 76% in 2024 [1] - The first version of the commercial insurance innovative drug list includes 19 drugs, laying the foundation for a multi-tiered medical security system [1] - The inclusion of nine innovative drugs from the Sci-Tech Innovation Board in the medical insurance list highlights the robust capabilities and vitality of these companies [1] Group 1: Innovative Drug Inclusion - Nine innovative drugs from Sci-Tech Innovation Board companies have been included in the medical insurance list, with several others successfully renewing or expanding their indications [1] - Junshi Biosciences' drug, Juntai® (generic name: Angrexis monoclonal antibody injection), is the only domestic PCSK9-targeted drug for patients intolerant to statins included in the new list [2] - Haichuang Pharmaceutical's first marketed drug, Hainaan® (generic name: Dihydrotestosterone enzalutamide soft capsule), received approval for market launch and is included in the 2025 medical insurance list, enhancing patient access [2] Group 2: Commercial Insurance Innovations - The first commercial health insurance innovative drug list complements the basic medical insurance, providing new possibilities for patients to access cutting-edge treatments [4] - Two advanced therapy drugs from BeiGene, including Baihe An® (generic name: Zhenidat monoclonal antibody injection), are among the first to be included in the commercial insurance list, marking a significant market access pathway for high-value innovative drugs [4] Group 3: Renewal and Expansion of Indications - Successful renewals of innovative drugs confirm their clinical value and market position, with BeiGene's Bai Ze An® (generic name: Tarelizumab injection) and Junshi Biosciences' Tuoyi® (generic name: Toripalimab injection) expanding their insurance coverage [5][6] - Junshi Biosciences' Tuoyi® has now been included for 12 indications in the national medical insurance list, showcasing the recognition of its clinical value and innovation by the National Medical Insurance Bureau [6] Group 4: R&D Investment and Development Cycle - Sci-Tech Innovation Board companies have maintained a high level of R&D investment, with total R&D spending reaching a new high in the first three quarters of 2025, growing over 10% year-on-year [6] - The R&D intensity of these companies stands at 42%, significantly surpassing the overall level of A-shares during the same period, indicating a solid cycle of "R&D investment - innovative results - insurance support - market returns - reinvestment in R&D" [6][7]

Core Insights - The National Healthcare Security Administration (NHSA) has released the 2025 National Medical Insurance Drug List, adding 114 new drugs, including 50 innovative drugs of Class A, and 19 drugs included in the first commercial insurance innovative drug list [1][4] Summary by Sections New Drug Additions - The 2025 National Medical Insurance Drug List primarily adds chemical drugs, with a rapid increase in biological products and some traditional Chinese medicine [1] - Out of the 114 new drugs, 112 were included through negotiation and bidding, while 2 were directly included from national procurement [1] - A total of 111 new drugs were approved in the last five years, with the number of Class A innovative drugs reaching a historical high of 50 [1] Financial Impact - As of October 2023, the NHSA has paid over 460 billion yuan for drugs under agreement, benefiting over 1 billion patients and driving related sales exceeding 670 billion yuan [2] - Basic medical insurance covers approximately 44% of the costs for innovative drugs, while commercial insurance covers about 7% [2] Evaluation and Selection Criteria - The selection process for new drugs has seen a low pass rate during expert reviews, with only 127 out of 311 drugs passing to the negotiation table this year [2] - Some drugs were not favored due to "involutionary innovation," where the clinical value does not significantly improve compared to existing drugs [3][4] - To be included in the list, drugs must meet at least one of three criteria: filling clinical gaps, superior efficacy, or better cost-effectiveness [4] Commercial Insurance Innovations - The newly introduced commercial health insurance innovative drug list emphasizes drug innovation and clinical value, with 19 out of 141 submitted drugs successfully negotiated for inclusion [5] - The drugs in the commercial insurance list include 9 Class A new drugs, addressing gaps in basic medical insurance coverage [5] Future Directions - The NHSA plans to continue annual adjustments to the drug list to meet evolving clinical needs and incorporate advancements in medical technology [6] - The focus will be on supporting domestic and innovative drugs, enhancing collaboration between commercial insurance and innovative pharmaceutical companies [6]

Core Viewpoint - The A-share market is expected to face short-term risks but may enter a preparation window for next year's expectations due to upcoming economic meetings and potential interest rate cuts by the Federal Reserve [2][6]. Group 1: Market Outlook - In November, the market was influenced by U.S. liquidity expectations, with strong performance in dividend and cyclical sectors, while growth stocks lagged [2][6]. - December may present a window for positioning as the Central Economic Work Conference approaches and the Federal Reserve is expected to lower interest rates [2][6]. Group 2: AI Applications - The company maintains a positive outlook on AI applications in the healthcare and consumer sectors, particularly in new technology sub-sectors [3][7]. - After an initial overestimation of AI application expectations, the market has adjusted to more rational forecasts, with significant infrastructure already in place for AI applications [3][7]. - The current low market expectations in the AI application field may lead to valuation recovery opportunities [3][7]. Group 3: Innovative Pharmaceuticals - In the innovative drug sector, two focus areas are identified: deep globalization of already business-developed (BD) companies and the confirmation of pipeline value for non-BD companies [4][9]. - Many innovative drug stocks have absorbed negative sentiment, but December lacks significant data releases or BD catalysts, shifting attention to the clinical data readout rhythm of potential heavy-hitting pipelines [4][9].

Investment Rating - The report suggests a focus on "innovation-driven" and "steady growth" strategies within the pharmaceutical sector, indicating a positive investment outlook for the industry [3][4]. Core Insights - The North Exchange's pharmaceutical and biotechnology sector comprises 21 companies, all classified as specialized and innovative, with a significant proportion being national and provincial champions [2][16]. - The report emphasizes the potential of innovative drugs, high-end medical devices, and robust generics as key investment areas, highlighting the importance of unique products and market share advantages [3][4]. - The medical device sector has shown the highest market value growth in 2025, with an increase of 130.47%, while traditional Chinese medicine has faced performance challenges [28][32]. Summary by Sections Industry Overview - The North Exchange's pharmaceutical sector includes five sub-sectors: traditional Chinese medicine, medical devices, medical aesthetics, biological products, and chemical pharmaceuticals [12][24]. - The average market capitalization of the 21 companies in this sector reached 3.643 billion yuan as of December 1, 2025, reflecting a year-to-date increase of 41.97% [21][23]. Sub-sector Analysis - The medical device industry led the market value growth in 2025, with a total market value increase from 6.818 billion yuan at the end of 2024 to 15.713 billion yuan by December 1, 2025 [28]. - The chemical pharmaceutical sector also performed well, with notable companies like Deyuan Pharmaceutical showing a revenue increase of 22% year-on-year in the first three quarters of 2025 [4][34]. Company Case Studies - **Innovative Drugs**: Norsland's gene therapy drug NL003 is nearing approval, targeting a significant patient population with a new treatment method [4][9]. - **Medical Devices**: Weizhu Zhiyuan focuses on smart orthopedic surgical navigation systems, emphasizing the importance of unique technology and market positioning [4][11]. - **Generics**: Deyuan Pharmaceutical is transitioning from generics to innovative drugs, with a solid historical performance and a focus on diabetes and hypertension treatments [4][34]. Performance Metrics - The report notes that the average PE TTM for the pharmaceutical sector was 32X as of December 1, 2025, with the medical device sector showing a higher valuation at 78X [15][55]. - Companies like Jinbo Biological and Norsland have seen significant stock price increases, with Jinbo's stock rising by 170.68% and Norsland by 113.10% in 2025 [41][42].

2025 年 12 月 10 日 行业研究 医保和商保目录并轨，扩容与提质并重，支持创新药高质量发展 ——2025 年版医保目录调整政策点评 作者 分析师：王明瑞 执业证书编号：S0930520080004 021-52523867 wangmingrui@ebscn.com 分析师：黄素青 执业证书编号：S0930521080001 021-52523570 huangsuqing@ebscn.com 行业与沪深 300 指数对比图 -12% -4% 4% 12% 20% 12/24 03/25 06/25 09/25 医药生物 沪深300 资料来源：Wind 要点 事件：2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布《国家基本医疗 保险、工伤保险和生育保险药品目录（2025 年）》以及首版《商业健康保险创新药 品目录（2025 年）》，要求进一步推动商业健康保险与基本医保的有效衔接。 点评： 医药生物 基本医保谈判成功率创 7 年新高，首版商保目录纳入 19 种药品。本次调整后，医 保目录内药品总数从 3159 种增加至 3253 种，其中西药 1857 种、中成药 1396 种， 协 ...

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) experienced a slight decline of 0.12% today, with a total trading volume exceeding 1.5 billion yuan [1] - The fund has seen a net inflow of over 1.1 billion yuan yesterday and more than 1 billion yuan today, accumulating a total of over 1.9 billion yuan in the last 20 days [1] - As of December 9, the latest scale of the Hong Kong Innovation Drug ETF reached over 23 billion yuan, leading its peers in the same category [1] Group 2: Federal Reserve and Market Sentiment - The Federal Reserve is expected to announce a 25 basis point rate cut, bringing the federal funds rate to a range of 3.5%-3.75% [3] - There is a notable division within the Federal Open Market Committee (FOMC), leading to the term "hawkish cut" being used, indicating that while a rate cut is expected, further cuts may not be imminent [3] Group 3: Pharmaceutical Sector Developments - The new National Medical Insurance Drug List has added 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, up from 76% last year [5][8] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, enhancing coverage for critical areas such as oncology, chronic diseases, and rare diseases [8] - The first commercial insurance innovative drug list has been released, including 19 drugs from 18 companies, aimed at improving access to high-value innovative drugs [6][13] Group 4: Investment Opportunities - The Hong Kong Innovation Drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for over 74% of its weight [15] - The index has shown a year-to-date increase of over 90%, outperforming other Hong Kong pharmaceutical indices [16] - The ETF's underlying assets are Hong Kong stocks, allowing for T+0 trading, which may attract more investors [16]

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2] Group 1: Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020, specializing in the research and commercialization of monoclonal antibodies and therapeutic proteins [7] - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7] - As of September 30, 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a strong product pipeline, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the EU, the UK, and Australia [2] - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2] Group 3: Collaborations and New Initiatives - On October 27, 2023, Junshi Biosciences announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3] - The company's subsidiary, JunTuo Biotech, is involved in the preclinical development of vaccines for monkeypox and Zika virus, indicating a focus on expanding its vaccine pipeline [3] Group 4: Market Performance - On December 10, Junshi Biosciences' stock rose by 0.58%, with a trading volume of 173 million yuan and a market capitalization of 37.269 billion yuan [1] - The stock has seen a net outflow of 7.0425 million yuan from major investors, indicating a reduction in holdings over the past two days [4][5]

Core Viewpoint - The technology innovation sector is experiencing a decline, with major indices such as the Sci-Tech 100 Index and the Sci-Tech Comprehensive Index dropping by 0.8% and 1.2% respectively, while the Sci-Tech 50 Index fell by 1.3% [1][3]. Group 1: Index Performance - The Sci-Tech 50 Index saw a decrease of 1.3% as of the midday close [3]. - The Sci-Tech 100 Index and the Sci-Tech Comprehensive Index both declined by 0.8% [1][3]. - The Sci-Tech 50 ETF (588080) recorded a net inflow of nearly 300 million yuan yesterday [1]. Group 2: Sector Composition - The Sci-Tech 50 Index is composed of 50 stocks with significant market capitalization and liquidity, prominently featuring "hard technology" companies, with over 65% in the semiconductor sector and nearly 80% combined in medical devices, software development, and photovoltaic equipment [3]. - The Sci-Tech 100 Index focuses on 100 medium-sized stocks with good liquidity, primarily in the electronics, pharmaceutical, and electrical equipment sectors, which together account for over 80% of the index [3]. - The Sci-Tech Comprehensive Index covers all market securities in the Sci-Tech board, focusing on core industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals, encompassing all 17 primary industries on the Sci-Tech board [3].

12月10日，港股创新药延续调整，核心标的港股通创新药ETF（520880）水面下方震荡，场内价格一度 逼近7月以来低点。阶段破位之际，低吸资金闻风而动，520880溢价飙升，显示买盘尤为活跃。 此前两日已有资金大举进场。数据显示，港股通创新药ETF（520880）近2日连续获超5600万元资金净 申购，合计超1.13亿元。 2、龙头占比大。前十大创新药龙头权重超72%，表征创新药硬核力量。 3、风险更可控。对流动性较差的成份股强制降权，有力管控尾部风险。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达72.57%, 龙头优势显著 | | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 百济神州 | 11.51 | 3,070 | | 1801.HK | 信达生物 | 10.19 | 1,613 | | 1177.HK | 中国生物制药 | 9.47 | 1,323 | | 9926.HK | 康方生物 | 8.99 | 1,132 | | 1093.HK | 石药集团 ...

对此，国信证券表示，此次商保创新药目录的发布，标志着我国商业健康保险在创新药支付领域迈出实 质性步伐，与基本医保目录形成错位互补，为创新药支付端开辟了"第二战场"，同时有效缓解了医保控 费压力与药企创新需求之间的长期矛盾，为我国创新药产业的健康发展注入动力。国家通过统一目录把 分散的特药需求标准化、把碎片化的赔付数据集中化，为行业提供了可复用的"公共基础设施"，相当于 为创新药市场提供了"销量加速器"，有助于深化医疗产业投资机会。 与此同时，近期资金正持续布局头部创新药赛道。Wind数据显示，截至12月9日，港股创新药ETF （513120）在此前连续8日获加仓后，12月9日再获资金净买入2.15亿元；该ETF最新规模达249亿元， 年内日均成交额超53亿元，是全市场同类规模最大、流动性最好的港股创新药主题指数基金。同时，该 ETF还支持T+0交易，为投资者提供了便捷高效的配置工具。 Wind数据显示，港股创新药ETF(513120，联接A/C类019670/019671)，高度聚焦港股市场优质生物科技 公司，覆盖创新药、基因治疗、前沿生物技术等细分领域龙头，"申万二级生物制品+化学制药"的合计 权重达90% ...